Pharmatech AI: Transforming Medicine with Next-Gen AI

MARKET POTENTIAL
                    $012345678900123456789001234567890                                         B                     i                     l                     l                     i                     o                     n

Global Drug Discovery Market

PAIN MEDS
                    $0123456789001234567890                                         B                     i                     l                     l                     i                     o                     n
Global Pain Relief Market
INITIAL MARKETCAP
                    $012345678900123456789001234567890                     k

$PCH Initial Market Capitalization

MARKET POTENTIAL
                    $012345678900123456789001234567890                                         B                     i                     l                     l                     i                     o                     n

Global Drug Discovery Market

PAIN MEDS
                    $0123456789001234567890                                         B                     i                     l                     l                     i                     o                     n
Global Pain Relief Market
INITIAL MARKETCAP
                    $012345678900123456789001234567890                     k

$PCH Initial Market Capitalization

That's what makes us unique.Why Pharmatech AI?

https://pharmatech-ai.com/wp-content/uploads/2025/04/Research-Location-Pharmatech-AI.png
We own & use our620k m² Research Center
Our Center features 60 hectares (120K m² indoor), energy-independent with 55 MWp solar (55 GWh/year), CO2-positive, and scalable enabling sustainable, large-scale industrial hemp production.
https://pharmatech-ai.com/wp-content/uploads/2025/05/AI-MDIP-1.png
We develop & offer anUnique AI Model 'AI-MDIP'
We develop an advanced GNN-Transformer AI predicting 250K–5M molecular interactions including 50K cannabis-specific compounds for precision drug discovery and bioactive optimization.
https://pharmatech-ai.com/wp-content/uploads/2025/05/MDIP-Practical-Laboratory-Grow.jpg
We own & use ourMDIP Practical Laboratory
Our 200 m² AI-powered Cannabis Lab (2025) generates 15K data points per cycle with full seed-to-flower data control ensuring reproducible precision breeding and advanced analytics.
Accelerating the Pharma Revolution

AI-Powered Drug Discovery

Pharmatech AI leverages AI-MDIP to revolutionize drug discovery, targeting a $137B drug discovery market with non-opioid pain solutions, high-growth cannabinoid therapies, and nanomedicine, backed by a 60-hectare campus and proprietary data for $500M-$1B exit potential.

What is Drug Discovery?We Solve Pharma’s Biggest Challenges with AI

Traditional drug discovery faces staggering challenges: 90% of clinical candidates fail due to safety or efficacy issues, stretching development to 12+ years and $2B+ per approved drug. Our AI-MDIP analyzes 5 million+ molecular interactions to predict success earlier, accelerating development while reducing costs and risk.
Faster Drug Discovery
0123456789001234567890                     %

faster by predicting molecular interactions through our AI-MDIP platform.

 

Cost Reduction
0123456789001234567890                     %

cheaper through replacing costly wet-lab experiments with precise in-silico simulations.

The Result?

Faster, safer, and more effective drug development – from chronic pain to neurological disorders. While the market grows to $450B, we turn data into patents, partnerships, and life-saving treatments.

Built with Leading Scientific AI FrameworksPowered by Cutting-Edge Research Technologies

Our AI platform combines powerful open-source technologies: PyTorch Geometric for graph-based drug discovery, DeepChem for molecular modeling, RDKit for cheminformatics, Deep Graph Library (DGL) for neural networks, and scikit-learn for machine learning. PyTorch and the PyTorch logo are trademarks of Facebook, Inc. Other logos are property of their respective owners.

https://pharmatech-ai.com/wp-content/uploads/2025/05/learn-Logo1.png
https://pharmatech-ai.com/wp-content/uploads/2025/05/deepchem-logo.png
https://pharmatech-ai.com/wp-content/uploads/2025/05/dgl-Logo1.png
https://pharmatech-ai.com/wp-content/uploads/2025/05/Pyg-Logo1.png
https://pharmatech-ai.com/wp-content/uploads/2025/05/Pytorch-Logo1.png
learn-Logo1
Pytorch-Logo1
Pyg-Logo1
dgl-Logo1
deepchem logo
“Drug discovery is like deciphering a secret language whose alphabet changes with every letter.”
Ercan Hayvali, M.Sc., Founder

Access Pharma's Billion-Dollar MarketIntroducing the $PCH Token

https://pharmatech-ai.com/wp-content/uploads/2025/05/PCH-Ecosystem-Pharmatech-AI-768x893.png
PCH Token Ecosystem
The PCH token, a high-growth utility token, offers investors a unique entry into the billion-dollar pharmaceutical market through Pharmatech AI’s innovative AI-driven platform.
We monetize cutting-edge research and our AI platform via lucrative pharma licenses, subscriptions, and a data marketplace, with stakers sharing 70% of profits, targeting $84M annually by 2028. Built on the BEP20 standard with a fixed 1B token supply, PCH empowers investors to stake for stablecoin profit sharing, engage in governance, and benefit from deflationary value growth through a buy-back-and-burn mechanism. Exclusive features like licensing auctions and community incentives ensure investors thrive in the booming pharmaceutical sector.
TOTAL SUPPLY
01234567890                     B

fixed PCH token supply, ensuring scarcity & long-term value potential.

STAKING REWARDS
                    $0123456789001234567890                     M
projected annual revenue share for stakers by 2028, paid quarterly in stablecoins.
“The science is clear that marijuana is a valuable medicine and should be treated as such with sensible legislation supporting its research and use.”
Sanjay Gupta, American Neurosurgeon

$PCH Tokenizes the Pharmaceutical RevolutionTokenomics & Allocation

Pharmatech AI’s tokenomics are designed for long-term success, with a fixed total supply of 1 billion $PCH ensuring no inflation. Funds raised will drive development, partnerships, and ecosystem growth. Carefully structured vesting schedules align incentives and promote stability for all stakeholders.

What were the fundraising rounds?

Pre-Seed: $0.00400 → $280.000 value

Seed: $0.00475 → $498.750 value

KOL Round: $0.00725 → $507.500 value

Public Round: $0.00975 → $1.316.250 value

Total Value: $2.602.500

When are tokens unlocked?

Core Team: 12-month cliff, then linear release over 36 months.

Advisors: 6-month cliff, then linear release over 12 months.

Pre-Seed/Seed: Partial TGE unlock, remainder vested over 12 months.

KOL/Public: Partial TGE unlock, remainder vested over 12 months.

Treasury: 40% at TGE, 60% linearly over 12 months.

What’s the listing price?

Launch Price: $0.00975 per $PCH

Initial MC (IMC): ~$494.8k

Fully Diluted MC (FDMC): ~$9.75M

Where can I trade $PCH?

CEX Listings: Multiple Tier 2 exchanges

DEX Availability: Immediate liquidity pools

Future Upgrades: T1 exchange negotiations ongoing

Pharmatech AI’s tokenomics are designed for long-term success, with a fixed total supply of 1 billion $PCH ensuring no inflation. Funds raised will drive development, partnerships, and ecosystem growth. Carefully structured vesting schedules align incentives and promote stability for all stakeholders.

What were the fundraising rounds?

Pre-Seed: $0.00400 → $280.000 value

Seed: $0.00475 → $498.750 value

KOL Round: $0.00725 → $507.500 value

Public Round: $0.00975 → $1.316.250 value

Total Value: $2.602.500

When are tokens unlocked?

Core Team: 12-month cliff, then linear release over 36 months.

Advisors: 6-month cliff, then linear release over 12 months.

Pre-Seed/Seed: Partial TGE unlock, remainder vested over 12 months.

KOL/Public: Partial TGE unlock, remainder vested over 12 months.

Treasury: 40% at TGE, 60% linearly over 12 months.

What’s the listing price?

Launch Price: $0.00975 per $PCH

Initial MC (IMC): ~$494.8k

Fully Diluted MC (FDMC): ~$9.75M

Where can I trade $PCH?

CEX Listings: Multiple Tier 2 exchanges

DEX Availability: Immediate liquidity pools

Future Upgrades: T1 exchange negotiations ongoing

Frequently Asked Questions FAQ

This FAQ addresses key questions to highlight the project's potential and benefits.
What is Pharmatech AI and their Mission?
Pharmatech AI is a company using artificial intelligence to transform how new drugs are discovered, especially in areas like pain relief and cannabinoid research. Their goal is to speed up and lower the cost of developing new drug combinations, making healthcare innovation more accessible.
What Technology Makes them Special?
They will develop the AI Multi-Drug Interaction Predictor (AI-MDIP), a high-tech AI model that predicts how different drugs interact, including cannabis compounds, using advanced methods like Graph Neural Networks. They also grow cannabis in their own lab to create unique data, giving them an edge over competitors.
How Does the PCH Token Work?
The PCH token, with a fixed supply of 1 billion, is used within their ecosystem for bidding on drug licenses, staking to earn revenue shares in stablecoins, voting on project decisions, and getting community rewards. A buy-back-and-burn strategy reduces the token supply, potentially increasing its value over time.
What’s the Market Potential?
The markets they target are huge and expanding: the global drug discovery market is expected to reach $137.72 billion by 2029, AI in drug discovery $7.1 billion by 2030, and medical cannabis $41.4 billion by 2030. They plan to earn $150-300 million from licensing by 2027 and $25 million yearly from subscriptions by 2028.
How Can Investors Benefit?
By holding PCH tokens, investors can stake them to receive 70% of platform revenues quarterly in stablecoins, see potential value growth from the buy-back-and-burn, and use tokens for ecosystem activities. They can also influence project decisions through governance, aligning their investment with Pharmatech AI’s success.
https://pharmatech-ai.com/wp-content/uploads/2025/05/Pharmatech-AI-FAQ.png

Our Team of Experts

https://pharmatech-ai.com/wp-content/uploads/2025/05/Ercan-Hayvali-M.SC_.jpg
CEO, Economist & AI Researcher

Ercan Hayvali, M.Sc.

https://pharmatech-ai.com/wp-content/uploads/2025/05/Christian-Tonn.jpg
Market Access Manager (Pharma)

Christian Tonn

https://pharmatech-ai.com/wp-content/uploads/2025/05/Miguel-Martinez.jpeg
Lead Cannabis Lab Analyst

Miguel Bermudez

https://pharmatech-ai.com/wp-content/uploads/2025/05/Sebastian-Picture.png
Head of Cannabis Alliances

Sebastian Reifegerste

https://pharmatech-ai.com/wp-content/uploads/2025/05/Mert-Enginer-PCH.jpg
Lead Research & IT Infrastructure

Mert Enginer

https://pharmatech-ai.com/wp-content/uploads/2025/05/Philipp-Bosch.jpg
Agricultural Research Director

Philipp Bösch

https://pharmatech-ai.com/wp-content/uploads/2025/05/Valera-320x320.jpeg
Advisor

Valera Vlasyuk

Tech Entrepreneur & Full-Stack Visionary
https://pharmatech-ai.com/wp-content/uploads/2025/05/Jan-Kriegelstein-320x320.jpeg
Advisor

Jan Kriegelstein

Chief Executive Officer, Synergy Media
https://pharmatech-ai.com/wp-content/uploads/2025/05/Synergy-Media-320x180.png
Incubator

Synergy Media

Digital Media Agency from Germany